17 03, 2023 SARS-CoV-2 Nsp2 contributes to inflammation by activating NF-kBNeal Evan Caminsky2023-03-17T09:37:00-04:00March 17, 2023|Funded Research Results, Pillar 3|
17 03, 2023 Natural evolution of SARS-CoV-2 variants in K18-ACE2 mice gives rise to more virulent virus and variant alleles associated with treatment resistanceNeal Evan Caminsky2023-03-17T09:32:07-04:00March 17, 2023|Funded Research Results, Pillar 3|
27 01, 2023 Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit stress granule formationNeal Evan Caminsky2023-01-27T15:58:35-05:00January 27, 2023|Funded Research Results, Pillar 3|
7 11, 2022 Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variantsNeal Evan Caminsky2022-11-22T18:37:06-05:00November 7, 2022|Funded Research Results, Pillar 3|
2 11, 2022 Identifying markers of emerging SARS-CoV-2 variants in patients with secondary immunodeficiencyNeal Evan Caminsky2022-11-15T09:12:37-05:00November 2, 2022|Funded Research Results, Pillar 3|
4 10, 2022 Cytokines and lipid mediators of inflammation in lungs of SARS-CoV-2 infected miceNeal Evan Caminsky2022-11-15T09:14:07-05:00October 4, 2022|Funded Research Results, Pillar 3|
30 09, 2022 A nanoparticle-based COVID-19 vaccine candidate elicits broad neutralizing antibodies and protects against SARS -CoV-2 infectionNeal Evan Caminsky2022-11-15T09:14:05-05:00September 30, 2022|Funded Research Results, Pillar 3|
27 09, 2022 Human coronaviruses disassemble processing bodiesNeal Evan Caminsky2022-11-15T09:14:02-05:00September 27, 2022|Funded Research Results, Pillar 3|
26 09, 2022 Monovalent and trivalent VSV-based COVID-19 vaccines elicit potent neutralizing antibodies and immunodominant CD8+ T cells against diverse SARS-CoV-2 variantsNeal Evan Caminsky2022-11-15T09:14:00-05:00September 26, 2022|Funded Research Results, Pillar 3|
